Podcast: Overall Survival in Enhertu vs Kadcyla for HER2+ MBC
Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer
Dec 9, 2022
Dr. Sara Hurvitz discusses new overall survival results from the DESTINY-Breast03 study.
2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.
At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla.
Listen to the episode to hear Dr. Hurvitz explain:
- overall survival and progression-free survival results
- severe side effects of Enhertu
- how the researchers managed any severe lung problems that developed in people receiving Enhertu
Comments
-
The presenter has not mentioned that there are side effects of enhertu other than ILD that are much more severe than Kadcyla to the extent of not wanting to live on treatment ...
It is good that there are options and I much we would rather have it than not but omitting that they are very different in how the majority of people feel on them is not honest IMO.
0
